• The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million

    Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries

    Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.”

    To request a sample copy / brochure of this report, please visit
    https://www.rootsanalysis.com/reports/310/request-sample.html

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:
     More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs
     An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters
     A detailed assessment of the current market landscape of BBB penetrant drugs.
     Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.
     An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.
     Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.
     An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.
     An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.
     An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).
     An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.
     An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.
     An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.
     A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.
     A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.
     An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain.
    A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :
     Type of Payment Model Adopted
     Upfront payments
     Milestone payments

     Type of Molecule
     Small Molecules
     Biologics

     Target Disease Indication
     Brain Metastases in Breast Cancer
     Glioblastoma Multiforme
     Hunter Syndrome
     Hurler Syndrome

     Leading Technology Platforms
     G®-Technology
     J-Brain Cargo® Technology
     LRP-1 Technology
     Trojan Horse Technology

     Leading Drug Developers
     2-BBB
     Angiochem
     ArmaGen
     JCR Pharmaceuticals

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific

    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))
     Frank S Walsh (Chief Executive Officer and Founder, Ossianix)
     Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)
     Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)
     Mathias Schmidt (Chief Executive Officer, ArmaGen)
     Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)
     Xavier Rivero (Chief Operating Officer, Sagetis Biotech)
     Carole Desseaux (Head of Clinical Affairs, CarThera)
     Jamal Temsamani (Head of Drug Development, Vect-Horus)
     Kevin Kit Parker (Professor, Wyss Institute, Harvard University)

    Key companies covered in the report
     Angiochem
     ArmaGen
     BioArctic
     Cyclenium Pharma
     Denali Therapeutics
     ICB International
     Iproteos
     JCR Pharmaceuticals
     Lauren Sciences
     Medesis Pharma
     Ossianix
     Vect-Horus

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development
    2. DNA-Encoded Libraries: Platforms and Services Market
    3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The blood-brain barrier (BBB) penetrating drugs market is estimated to be worth USD 900 million Advances in biotechnology have enabled the development of versatile in vitro (static and dynamic), in vivo (micro-dialysis), and in situ (brain perfusion) blood–brain barrier models, allowing more effective and safe delivery of drugs across brain capillaries Over time, extensive R&D efforts have resulted in the development of a number of versatile BBB penetration technologies. These technologies have been designed either to externally alter the permeability of the blood csf barrier or augment the BBB penetrating capabilities of compatible pharmacological interventions. Roots Analysis is pleased to announce the publication of its recent study, titled, “Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics.” To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/310/request-sample.html The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of BBB penetration technologies and affiliated drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:  More than 110 drugs, capable of penetrating this elusive barrier are currently being evaluated for the treatment of CNS drugs disorders; there are 35+ technology platforms for the development of BBB penetrant drugs  An overview of the overall landscape of BBB penetration technologies, featuring an in-depth analysis of the technologies based on a number of parameters  A detailed assessment of the current market landscape of BBB penetrant drugs.  Identification of contemporary market trends depicted using three schematic representations, which include [A] a tree map representation, [B] a bubble analysis and [C] an informative heptagon representation.  An insightful competitiveness analysis of BBB penetration technologies, taking into consideration the supplier power and key technology specific information.  Elaborate profiles of prominent technology developers that are engaged in the development of at least four drugs.  An analysis of the partnerships that have been established in the domain, in the period between 2014 and 2020.  An elaborate discussion on the deal structures of various types of technology licensing agreements inked in this domain.  An analysis of the investments made in the domain, in the period between 2014 and 2020 (till March).  An in-depth analysis of the various patents that have been filed / granted related to BBB penetration technologies, till November 2019.  An insightful chessboard analysis highlighting the most preferred / popular drug development strategies / paths adopted by majority of the drug developers (with clinical candidates) in order to progress their lead drug candidates.  An assessment of the most commonly targeted disorders affecting the central nervous system , shortlisted on the basis of number of BBB penetrant drugs in development.  A list of 240+ drug developers targeting Alzheimer’s disease and Parkinson’s disease that are likely to partner with BBB penetration technology providers.  A case study highlighting the working principle of the most common approaches that are being employed for the development of BBB penetration technologies.  An informative analysis of contemporary Google Trends in the time period between 2015 and 2019 (till December) and insights generated from recent news articles related to the BBB, indicating the increasing popularity of this domain. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) :  Type of Payment Model Adopted  Upfront payments  Milestone payments  Type of Molecule  Small Molecules  Biologics  Target Disease Indication  Brain Metastases in Breast Cancer  Glioblastoma Multiforme  Hunter Syndrome  Hurler Syndrome  Leading Technology Platforms  G®-Technology  J-Brain Cargo® Technology  LRP-1 Technology  Trojan Horse Technology  Leading Drug Developers  2-BBB  Angiochem  ArmaGen  JCR Pharmaceuticals  Key Geographical Regions  North America  Europe  Asia-Pacific Transcripts of interviews held with the following senior level representatives of stakeholder companies  Ram Bhatt (Chief Executive Officer, Chairman and Founder, Innovative California Biosciences International (ICBI))  Frank S Walsh (Chief Executive Officer and Founder, Ossianix)  Pieter Gaillard (Chief Executive Officer and Co-Founder, 2-BBB)  Rob Hutchison (Chief Executive Officer and Chairman, biOasis Technologies)  Mathias Schmidt (Chief Executive Officer, ArmaGen)  Mark L Peterson (Chief Operating Officer, Cyclenium Pharma)  Xavier Rivero (Chief Operating Officer, Sagetis Biotech)  Carole Desseaux (Head of Clinical Affairs, CarThera)  Jamal Temsamani (Head of Drug Development, Vect-Horus)  Kevin Kit Parker (Professor, Wyss Institute, Harvard University) Key companies covered in the report  Angiochem  ArmaGen  BioArctic  Cyclenium Pharma  Denali Therapeutics  ICB International  Iproteos  JCR Pharmaceuticals  Lauren Sciences  Medesis Pharma  Ossianix  Vect-Horus For additional details, please visit https://www.rootsanalysis.com/reports/view_document/blood-brain-barrier-drug-delivery/310.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Novel Coronavirus (Covid-19): Preventive Vaccines, Therapeutics and Diagnostics in Development 2. DNA-Encoded Libraries: Platforms and Services Market 3. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Blood-Brain Barrier (BBB) | Industry Analysis | Market Size | 2030
    Blood-Brain Barrier (BBB) Market, 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and Therapeutics Nanoparticle based Approaches)
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • CBD Serum Stem Cell- Swiss Apple
    Athens, Tx
    Extracted from a rare apple, Swiss apple stem cells has anti-aging properties to promote skin renewal and longevity. By rejuvenating the skin cells, it can reduce the appearance of fine lines and wrinkles. https://nuteirhemp.com/product/cbd-serum-stem-cell-swiss-apple/
    Extracted from a rare apple, Swiss apple stem cells has anti-aging properties to promote skin renewal and longevity. By rejuvenating the skin cells, it can reduce the appearance of fine lines and wrinkles. https://nuteirhemp.com/product/cbd-serum-stem-cell-swiss-apple/
    Type
    New
    Price
    $25.00 (USD)
    Status
    In stock
    0 Comments 0 Shares
  • With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis

    With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions
     Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).
     An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
     An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.
     A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
     An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)
     A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.
     A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.
     A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.
     An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Source of Stem Cell
     Allogeneic
     Autologous

     Origin of Stem Cell
     Adult
     Embryonic

     Type of Stem Cell
     Hematopoietic
     Mesenchymal
     Progenitor
     Others

     Lineage of Stem Cell
     Adipose Tissue
     Bone Marrow
     Cord Blood
     Others

     Route of Administration
     Intraarticular
     Intracoronary
     Intramuscular
     Intramyocardial
     Intrathecal
     Intravenous
     Surgical Implantations
     Others

     Therapeutic Area
     Autoimmune / Inflammatory Disorder
     Cardiovascular Disorders
     Metabolic Disorder
     Musculoskeletal Disorders
     Oncological Disorders
     Neurological Disorders
     Ophthalmic Disorders
     Others

     End Users
     Ambulatory Surgery Centers
     Hospitals
     Specialty Clinics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific and Rest of the World

     Transcripts of interviews held with the following senior level representatives of stakeholder companies
     William L Rust (Founder and Chief Executive Officer, Seraxis)
     Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
     Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
     Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
     Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)
     Gilles Devillers (President, Bio Elpida)
     Fiona Bellot (Business Development Manager, Roslin Cell Therapies)
     David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

    Key companies covered in the report
     Anterogen
     Athersys
     CHABiotech
     Cytopeutics
     Hope Biosciences
     Japan Regenerative Medicine
     Lineage Cell Therapeutics
     Orchard Therapeutics
     Osiris Therapeutics
     Pluristem Therapeutics
     Promithera Biosciences
     Regenexx
     Stempeutics Research
     SCM Life Sciences
     TICEBA

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

    Other Recent Offerings
    1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
    2. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
    4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic. Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions  Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).  An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.  An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.  A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.  An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)  A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.  A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.  A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Source of Stem Cell  Allogeneic  Autologous  Origin of Stem Cell  Adult  Embryonic  Type of Stem Cell  Hematopoietic  Mesenchymal  Progenitor  Others  Lineage of Stem Cell  Adipose Tissue  Bone Marrow  Cord Blood  Others  Route of Administration  Intraarticular  Intracoronary  Intramuscular  Intramyocardial  Intrathecal  Intravenous  Surgical Implantations  Others  Therapeutic Area  Autoimmune / Inflammatory Disorder  Cardiovascular Disorders  Metabolic Disorder  Musculoskeletal Disorders  Oncological Disorders  Neurological Disorders  Ophthalmic Disorders  Others  End Users  Ambulatory Surgery Centers  Hospitals  Specialty Clinics  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World  Transcripts of interviews held with the following senior level representatives of stakeholder companies  William L Rust (Founder and Chief Executive Officer, Seraxis)  Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)  Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)  Kikuo Yasui (Director and Chief Operating Officer, Heartseed)  Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)  Gilles Devillers (President, Bio Elpida)  Fiona Bellot (Business Development Manager, Roslin Cell Therapies)  David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the report  Anterogen  Athersys  CHABiotech  Cytopeutics  Hope Biosciences  Japan Regenerative Medicine  Lineage Cell Therapeutics  Orchard Therapeutics  Osiris Therapeutics  Pluristem Therapeutics  Promithera Biosciences  Regenexx  Stempeutics Research  SCM Life Sciences  TICEBA For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent Offerings 1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030 2. Antibody Drug Conjugates Market (5th Edition), 2019-2030 3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research
    Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The Companion Diagnostics Development Services Market
    In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Companion Diagnostics Development Services Market, 2020-2030”

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of more than 180 companies offering companion diagnostics services.
     Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered).
     An analysis of the partnerships that have been established in this domain, in the recent past.
     A list of stakeholders generated based on a detailed analysis of a set of relevant parameters, which are anticipated to partner with companion diagnostics services providers in the foreseen future.
     A detailed competitiveness analysis of companion diagnostics services providers, featuring insightful pictorial summaries and representations.
     A comparative analysis of the needs of different stakeholders involved in this domain.
     A discussion on various steps of the development operations of a companion diagnostic and the cost requirements across each of the stages.
     An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Type of Services
     Feasibility Studies
     Assay Development
     Analytical Validation
     Clinical Validation
     Manufacturing
     Type of Analytical Technique
     in situ hybridization / Immunohistochemistry
     Next Generation Sequencing
     Polymerase Chain Reaction
     Others
     Key Geographical Region
     North America
     Europe
     Asia-Pacific and the Rest of the World


    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)
     Paul Kortschak (Senior Vice President, Novodiax)
     Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
     Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)


    Key companies covered in the https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

     Almac Diagnostic Services
     Asuragen
     BARD1 Life Sciences
     BioMarCare Technologies
     Covance
     Gencurix
     Geneuity
     Leica Biosystems
     Macrogen
     MD Biosciences
     R-Biopharm
     ResearchDx
     Tepnel Pharma Services

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

    Other Recent Offerings
    1. Neoantigen Targeted Therapies Market, 2019-2030
    2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
    3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The Companion Diagnostics Development Services Market In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise Roots Analysis is pleased to announce the publication of its recent study, titled, “Companion Diagnostics Development Services Market, 2020-2030” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of more than 180 companies offering companion diagnostics services.  Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered).  An analysis of the partnerships that have been established in this domain, in the recent past.  A list of stakeholders generated based on a detailed analysis of a set of relevant parameters, which are anticipated to partner with companion diagnostics services providers in the foreseen future.  A detailed competitiveness analysis of companion diagnostics services providers, featuring insightful pictorial summaries and representations.  A comparative analysis of the needs of different stakeholders involved in this domain.  A discussion on various steps of the development operations of a companion diagnostic and the cost requirements across each of the stages.  An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Services  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Analytical Technique  in situ hybridization / Immunohistochemistry  Next Generation Sequencing  Polymerase Chain Reaction  Others  Key Geographical Region  North America  Europe  Asia-Pacific and the Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies  Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)  Paul Kortschak (Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)  Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories) Key companies covered in the https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html  Almac Diagnostic Services  Asuragen  BARD1 Life Sciences  BioMarCare Technologies  Covance  Gencurix  Geneuity  Leica Biosystems  Macrogen  MD Biosciences  R-Biopharm  ResearchDx  Tepnel Pharma Services For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html Other Recent Offerings 1. Neoantigen Targeted Therapies Market, 2019-2030 2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Companion Diagnostics Services | Industry Analysis | Market Size | 2030
    Market research report focused on companion diagnostics service providers; details include current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The Companion Diagnostics Development Services Market
    In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise
    Roots Analysis is pleased to announce the publication of its recent study, titled, “Companion Diagnostics Development Services Market, 2020-2030”

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of more than 180 companies offering companion diagnostics services.
     Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered).
     An analysis of the partnerships that have been established in this domain, in the recent past.
     A list of stakeholders generated based on a detailed analysis of a set of relevant parameters, which are anticipated to partner with companion diagnostics services providers in the foreseen future.
     A detailed competitiveness analysis of companion diagnostics services providers, featuring insightful pictorial summaries and representations.
     A comparative analysis of the needs of different stakeholders involved in this domain.
     A discussion on various steps of the development operations of a companion diagnostic and the cost requirements across each of the stages.
     An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Type of Services
     Feasibility Studies
     Assay Development
     Analytical Validation
     Clinical Validation
     Manufacturing
     Type of Analytical Technique
     in situ hybridization / Immunohistochemistry
     Next Generation Sequencing
     Polymerase Chain Reaction
     Others
     Key Geographical Region
     North America
     Europe
     Asia-Pacific and the Rest of the World


    Transcripts of interviews held with the following senior level representatives of stakeholder companies
     Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)
     Paul Kortschak (Senior Vice President, Novodiax)
     Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
     Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)


    Key companies covered in the https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

     Almac Diagnostic Services
     Asuragen
     BARD1 Life Sciences
     BioMarCare Technologies
     Covance
     Gencurix
     Geneuity
     Leica Biosystems
     Macrogen
     MD Biosciences
     R-Biopharm
     ResearchDx
     Tepnel Pharma Services

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html

    Other Recent Offerings
    1. Neoantigen Targeted Therapies Market, 2019-2030
    2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030
    3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Gaurav Chaudhary
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The Companion Diagnostics Development Services Market In the last couple of years, a record number of personalized therapeutic products were approved in the US, establishing an urgent need for companion diagnostics and causing many drug developers to actively seek external support and expertise Roots Analysis is pleased to announce the publication of its recent study, titled, “Companion Diagnostics Development Services Market, 2020-2030” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of more than 180 companies offering companion diagnostics services.  Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered).  An analysis of the partnerships that have been established in this domain, in the recent past.  A list of stakeholders generated based on a detailed analysis of a set of relevant parameters, which are anticipated to partner with companion diagnostics services providers in the foreseen future.  A detailed competitiveness analysis of companion diagnostics services providers, featuring insightful pictorial summaries and representations.  A comparative analysis of the needs of different stakeholders involved in this domain.  A discussion on various steps of the development operations of a companion diagnostic and the cost requirements across each of the stages.  An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Services  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Analytical Technique  in situ hybridization / Immunohistochemistry  Next Generation Sequencing  Polymerase Chain Reaction  Others  Key Geographical Region  North America  Europe  Asia-Pacific and the Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companies  Anton Iliuk (President, Chief Technology Officer Tymora Analytical Operations)  Paul Kortschak (Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)  Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories) Key companies covered in the https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html  Almac Diagnostic Services  Asuragen  BARD1 Life Sciences  BioMarCare Technologies  Covance  Gencurix  Geneuity  Leica Biosystems  Macrogen  MD Biosciences  R-Biopharm  ResearchDx  Tepnel Pharma Services For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html Other Recent Offerings 1. Neoantigen Targeted Therapies Market, 2019-2030 2. Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030 3. Global Stem Cells Market: Focus on Clinical Therapies, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Companion Diagnostics Services | Industry Analysis | Market Size | 2030
    Market research report focused on companion diagnostics service providers; details include current market landscape and future growth opportunities
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 by Roots Analysis
    With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious op timism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions
     Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).
     An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
     An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.
     A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
     An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)
     A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.
     A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.
     A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.
     An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Source of Stem Cell
     Allogeneic
     Autologous

     Origin of Stem Cell
     Adult
     Embryonic

     Type of Stem Cell
     Hematopoietic
     Mesenchymal
     Progenitor
     Others

     Lineage of Stem Cell
     Adipose Tissue
     Bone Marrow
     Cord Blood
     Others

    To request for report - https://www.rootsanalysis.com/reports/296/request-sample.html

     Route of Administration
     Intraarticular
     Intracoronary
     Intramuscular
     Intramyocardial
     Intrathecal
     Intravenous
     Surgical Implantations
     Others

     Therapeutic Area
     Autoimmune / Inflammatory Disorder
     Cardiovascular Disorders
     Metabolic Disorder
     Musculoskeletal Disorders
     Oncological Disorders
     Neurological Disorders
     Ophthalmic Disorders
     Others

     End Users
     Ambulatory Surgery Centers
     Hospitals
     Specialty Clinics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific and Rest of the World


    Key companies covered in the report
     Anterogen
     Athersys
     CHABiotech
     Cytopeutics
     Hope Biosciences
     Japan Regenerative Medicine
     Lineage Cell Therapeutics
     Orchard Therapeutics
     Osiris Therapeutics
     Pluristem Therapeutics
     Promithera Biosciences
     Regenexx
     Stempeutics Research
     SCM Life Sciences
     TICEBA

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

    Other Recent Offerings
    1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
    2. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
    4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 by Roots Analysis With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious op timism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic. Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions  Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).  An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.  An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.  A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.  An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)  A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.  A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.  A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Source of Stem Cell  Allogeneic  Autologous  Origin of Stem Cell  Adult  Embryonic  Type of Stem Cell  Hematopoietic  Mesenchymal  Progenitor  Others  Lineage of Stem Cell  Adipose Tissue  Bone Marrow  Cord Blood  Others To request for report - https://www.rootsanalysis.com/reports/296/request-sample.html  Route of Administration  Intraarticular  Intracoronary  Intramuscular  Intramyocardial  Intrathecal  Intravenous  Surgical Implantations  Others  Therapeutic Area  Autoimmune / Inflammatory Disorder  Cardiovascular Disorders  Metabolic Disorder  Musculoskeletal Disorders  Oncological Disorders  Neurological Disorders  Ophthalmic Disorders  Others  End Users  Ambulatory Surgery Centers  Hospitals  Specialty Clinics  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World Key companies covered in the report  Anterogen  Athersys  CHABiotech  Cytopeutics  Hope Biosciences  Japan Regenerative Medicine  Lineage Cell Therapeutics  Orchard Therapeutics  Osiris Therapeutics  Pluristem Therapeutics  Promithera Biosciences  Regenexx  Stempeutics Research  SCM Life Sciences  TICEBA For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent Offerings 1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030 2. Antibody Drug Conjugates Market (5th Edition), 2019-2030 3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research
    Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Global Induced Pluripotent Stem Cells Market report published by Reports and Data offers a comprehensive analysis of the Induced Pluripotent Stem Cells market with regards to market share, market size, revenue growth, trends and demands, drivers and restraints, competitive scenario, business landscape, and regional bifurcation. The report has been generated by extensive secondary research with updated and latest information of the global Induced Pluripotent Stem Cells market further validated and verified by the industry experts and professionals. The report also offers forecast estimation about segments and sub-segments expected to show lucrative growth over the forecast period. The report, additionally, offers a comprehensive SWOT analysis and Porter’s Five Forces analysis to offer a better understanding of the competitive landscape of the industry.
    Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3551

    The report focuses on the comprehensive analysis of the competitive landscape along with detailed company profiles, market share, product portfolio, financial standings, market reach, global position, and strategic business expansion plans.
    Some of the players profiled in the report are
    Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc.
    The report sheds light on mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches among others. It also discusses in detail the technological advancements, product developments, and research and development activities of each key company.
    Further the report segments the Induced Pluripotent Stem Cells market on the basis of product types, applications, end-uses, and regions. The report discusses in detail the key factors influencing revenue growth of the segments and market growth in key regions. It also discusses economic growth, technological advancement, and presence of key players in each major geographical region.
    Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3551

    Derived Cell Type Outlook (Revenue in USD Million; 2017–2027)
    • Amniotic Cells
    • Fibroblasts
    • Keratinocytes
    • Hepatocytes
    • Others
    Application Outlook (Revenue in USD Million; 2017–2027)
    • Drug Development
    • Toxicity Testing
    • Regenerative Medicine
    • Academic
    End-User Outlook (Revenue in USD Million; 2017–2027)
    • Hospitals
    • Research Institutions
    Market Segmentation by Regions:
    • North America (U.S.A., Canada)
    • Europe (U.K., Italy, Germany, France, Rest of Europe)
    • Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
    To know more about the report @ https://www.reportsanddata.com/report-detail/induced-pluripotent-stem-cells-market

    Key Points Covered in the Report:
    • Key insights into the latest growth trends, developments, technological and product advancements, and research and development scenario
    • Analysis of micro- and macro-economic factors and regulatory framework
    • In-depth evaluation of factors such as cost, capacity, rates of production and consumption, gross revenue, profit margin, demand and supply ratio, import/export, market share, market size, and market trends
    • SWOT analysis, Porter’s Five Forces Analysis, investment return analysis, and feasibility analysis to offer a comprehensive view of the competitive landscape
    • Strategic recommendations to established market players and new entrants to overcome limitations and entry-level barriers in the global market landscape
    • A comprehensive 8 year assessment of the global Induced Pluripotent Stem Cells market for the period 2021-2027
    • Analysis of market drivers, restraints, challenges, limitations, threats, growth prospects and opportunities
    Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3551

    Thank you for reading the report. The report can be customize as per requirements of the clients. For further information or query about customization, please reach out to us and we will offer you the report best suited for your needs.
    Global Induced Pluripotent Stem Cells Market report published by Reports and Data offers a comprehensive analysis of the Induced Pluripotent Stem Cells market with regards to market share, market size, revenue growth, trends and demands, drivers and restraints, competitive scenario, business landscape, and regional bifurcation. The report has been generated by extensive secondary research with updated and latest information of the global Induced Pluripotent Stem Cells market further validated and verified by the industry experts and professionals. The report also offers forecast estimation about segments and sub-segments expected to show lucrative growth over the forecast period. The report, additionally, offers a comprehensive SWOT analysis and Porter’s Five Forces analysis to offer a better understanding of the competitive landscape of the industry. Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/3551 The report focuses on the comprehensive analysis of the competitive landscape along with detailed company profiles, market share, product portfolio, financial standings, market reach, global position, and strategic business expansion plans. Some of the players profiled in the report are Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc. The report sheds light on mergers and acquisitions, joint ventures, collaborations, partnerships, and product launches among others. It also discusses in detail the technological advancements, product developments, and research and development activities of each key company. Further the report segments the Induced Pluripotent Stem Cells market on the basis of product types, applications, end-uses, and regions. The report discusses in detail the key factors influencing revenue growth of the segments and market growth in key regions. It also discusses economic growth, technological advancement, and presence of key players in each major geographical region. Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/3551 Derived Cell Type Outlook (Revenue in USD Million; 2017–2027) • Amniotic Cells • Fibroblasts • Keratinocytes • Hepatocytes • Others Application Outlook (Revenue in USD Million; 2017–2027) • Drug Development • Toxicity Testing • Regenerative Medicine • Academic End-User Outlook (Revenue in USD Million; 2017–2027) • Hospitals • Research Institutions Market Segmentation by Regions: • North America (U.S.A., Canada) • Europe (U.K., Italy, Germany, France, Rest of Europe) • Asia-Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA) To know more about the report @ https://www.reportsanddata.com/report-detail/induced-pluripotent-stem-cells-market Key Points Covered in the Report: • Key insights into the latest growth trends, developments, technological and product advancements, and research and development scenario • Analysis of micro- and macro-economic factors and regulatory framework • In-depth evaluation of factors such as cost, capacity, rates of production and consumption, gross revenue, profit margin, demand and supply ratio, import/export, market share, market size, and market trends • SWOT analysis, Porter’s Five Forces Analysis, investment return analysis, and feasibility analysis to offer a comprehensive view of the competitive landscape • Strategic recommendations to established market players and new entrants to overcome limitations and entry-level barriers in the global market landscape • A comprehensive 8 year assessment of the global Induced Pluripotent Stem Cells market for the period 2021-2027 • Analysis of market drivers, restraints, challenges, limitations, threats, growth prospects and opportunities Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/3551 Thank you for reading the report. The report can be customize as per requirements of the clients. For further information or query about customization, please reach out to us and we will offer you the report best suited for your needs.
    Induced Pluripotent Stem Cells Market | Size, Growth & Trends
    Induced Pluripotent Stem Cells Market is estimated to reach a valuation of USD 2.50 billion by 2027, delivering a CAGR of around 8.2%. The increasing scope of research in the field, is propelling to the growth of the Induced Pluripotent Stem Cells Market.
    WWW.REPORTSANDDATA.COM
    0 Comments 0 Shares

  • The global live cell imaging market to reach USD 4.47 billion by 2028 at a CAGR of 9.1%, according to the latest report by Reports and Data. Increasing incidences of cancer, and adoption of live cell imaging techniques like high-content screening (HCS) to study microscopic behaviour of cells, are some key factors expected to drive market revenue growth over the forecast period. Increasing government funding on research and development activities, is further drive the market growth.
    Live cell imaging is a technique to study microscopic structure of live cells through images captured by high-content screening techniques. Live cell screening is also used to study cellular integrity, protein trafficking, enzyme activity, localization of molecules, exocytosis and endocytosis. Scientists can observe, study live cell functionalities through image screening techniques. Increasing demand of analysing and identifying drug safety and toxicity is one of the key factors expected to boost market revenue growth over the forecast period.
    There are lucrative opportunities for the market players operating in the global live cell imaging market. Pharmaceutical companies are developing biotechnology-based personalized medicines by using image screening techniques. Growth in biopharmaceutical industry is a contributing factor to the market growth. However, lack of availability of skilled professionals, high costs of instruments required for high-content screening, and increasing maintenance cost of these instruments are some of the major factors expected to hamper live cell imaging market growth to a certain extent over the forecast period.
    Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1749
    The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances.
    Key players in the market include
    Carl Zeiss, Meditec AG, Leica Microsystems, Nikon Corporation, Becton, Dickinson and Company, GE Healthcare, Olympus Corporation, Thermo Fisher Scientific, Millipore Sigma, PerkinElmer and Molecular Devices.
    Furthermore, the report segments Live Cell Imaging market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period.
    Product Outlook (Revenue, USD Billion; 2018 – 2028)
    • Instruments
    • Microscopes
    • Cell Analyzers
    • Image Capturing
    • Consumables
    • Software
    • Others
    Application Outlook (Revenue, USD Billion; 2018 – 2028)
    • Cell Biology
    • Stem Cells
    • Development Biology
    • Drug Discovery
    • Others
    Technology Outlook (Revenue, USD Billion; 2018 – 2028)
    • Fluorescence Resonance Energy Transfer (FRET)
    • Time Lapse Microscopy
    • Fluorescence Recovery after Photobleaching (FRAP)
    • High content screening (HCS)
    • Others

    End Use Outlook (Revenue, USD Billion; 2018 – 2028)
    • Pharmaceutical and Biotechnology Companies
    • Research Institutes
    • Hospitals
    • Diagnostics Laboratories
    • Others
    For a better understanding of the global Live Cell Imaging market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region.

    Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1749
    In-depth regional analysis includes:
    • North America (U.S., Canada, Mexico)
    • Europe (Italy, U.K., Germany, France, Rest of EU)
    • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC)
    • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America)
    • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
    To know more about the report @ https://www.reportsanddata.com/report-detail/live-cell-imaging-market
    Benefits of the Global Live Cell Imaging Report:
    • Comprehensive analysis of the opportunities and risks of the Live Cell Imaging market
    • Detailed study of the latest product and technological developments and innovations of the Live Cell Imaging market
    • Business strategies and plans are analysed for understanding the Live Cell Imaging market scenario
    • Revenue forecast of Live Cell Imaging market for the forecast period 2020-2028
    • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities
    • Latest and emerging market trends analysis and their impact on product and application demand
    • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others
    • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility
    Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1749
    Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements.
    Browse More Reports :
    BCG Vaccine Market Statistics
    Targeted RNA Sequencing Market Report

    To know more about Press Release report @ https://www.reportsanddata.com/press-release/global-live-cell-imaging-market


    About Reports and Data
    Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
    Contact Us:
    John W
    Head of Business Development
    Reports and Data | Web: www.reportsanddata.com
    Direct Line: +1-212-710-1370
    E-mail: sales@reportsanddata.com
    The global live cell imaging market to reach USD 4.47 billion by 2028 at a CAGR of 9.1%, according to the latest report by Reports and Data. Increasing incidences of cancer, and adoption of live cell imaging techniques like high-content screening (HCS) to study microscopic behaviour of cells, are some key factors expected to drive market revenue growth over the forecast period. Increasing government funding on research and development activities, is further drive the market growth. Live cell imaging is a technique to study microscopic structure of live cells through images captured by high-content screening techniques. Live cell screening is also used to study cellular integrity, protein trafficking, enzyme activity, localization of molecules, exocytosis and endocytosis. Scientists can observe, study live cell functionalities through image screening techniques. Increasing demand of analysing and identifying drug safety and toxicity is one of the key factors expected to boost market revenue growth over the forecast period. There are lucrative opportunities for the market players operating in the global live cell imaging market. Pharmaceutical companies are developing biotechnology-based personalized medicines by using image screening techniques. Growth in biopharmaceutical industry is a contributing factor to the market growth. However, lack of availability of skilled professionals, high costs of instruments required for high-content screening, and increasing maintenance cost of these instruments are some of the major factors expected to hamper live cell imaging market growth to a certain extent over the forecast period. Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1749 The report provides an in-depth analysis of the key developments and innovations of the market such as research and development advancements, product launches, mergers & acquisitions, joint ventures, partnerships, government deals, and collaborations. The report offers a comprehensive assessment of key players in the market along with their global position, financial standing, business expansion plans, production and manufacturing capacity, and strategic alliances. Key players in the market include Carl Zeiss, Meditec AG, Leica Microsystems, Nikon Corporation, Becton, Dickinson and Company, GE Healthcare, Olympus Corporation, Thermo Fisher Scientific, Millipore Sigma, PerkinElmer and Molecular Devices. Furthermore, the report segments Live Cell Imaging market on the basis of key product types and applications and provides details about the revenue growth, revenue CAGR, and revenue share each segment is expected to register over the forecast period. Product Outlook (Revenue, USD Billion; 2018 – 2028) • Instruments • Microscopes • Cell Analyzers • Image Capturing • Consumables • Software • Others Application Outlook (Revenue, USD Billion; 2018 – 2028) • Cell Biology • Stem Cells • Development Biology • Drug Discovery • Others Technology Outlook (Revenue, USD Billion; 2018 – 2028) • Fluorescence Resonance Energy Transfer (FRET) • Time Lapse Microscopy • Fluorescence Recovery after Photobleaching (FRAP) • High content screening (HCS) • Others End Use Outlook (Revenue, USD Billion; 2018 – 2028) • Pharmaceutical and Biotechnology Companies • Research Institutes • Hospitals • Diagnostics Laboratories • Others For a better understanding of the global Live Cell Imaging market dynamics, a regional analysis of the market across key geographical areas is offered in the report. The market is spread across key geographical regions such as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is analysed on the basis of the market scenario in the major countries of the regions to provide a deeper understanding of the market. It provides insights into production and consumption patterns, supply and demand ratio, export/import, current and emerging trends and demands, market share, market size, revenue contribution, and presence of key players in each region. Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1749 In-depth regional analysis includes: • North America (U.S., Canada, Mexico) • Europe (Italy, U.K., Germany, France, Rest of EU) • Asia Pacific (India, China, Japan, South Korea, Australia, Rest of APAC) • Latin America (Chile, Brazil, Argentina, Peru, Rest of Latin America) • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA) To know more about the report @ https://www.reportsanddata.com/report-detail/live-cell-imaging-market Benefits of the Global Live Cell Imaging Report: • Comprehensive analysis of the opportunities and risks of the Live Cell Imaging market • Detailed study of the latest product and technological developments and innovations of the Live Cell Imaging market • Business strategies and plans are analysed for understanding the Live Cell Imaging market scenario • Revenue forecast of Live Cell Imaging market for the forecast period 2020-2028 • Comprehensive analysis of the drivers, constraints, limitations, challenges, and opportunities • Latest and emerging market trends analysis and their impact on product and application demand • Study of recent M&A, joint ventures, collaborations, partnerships, product launches and brand promotions among others • Extensive SWOT analysis and Porter’s Five Forces analysis along with investment return analysis and feasibility Request a customization of the report @ https://www.reportsanddata.com/request-customization-form/1749 Thank you for reading our report. Please get in touch with us to know more about the report and customization of the report. Our team will ensure the report is tailored to meet your requirements. Browse More Reports : BCG Vaccine Market Statistics Targeted RNA Sequencing Market Report To know more about Press Release report @ https://www.reportsanddata.com/press-release/global-live-cell-imaging-market About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John W Head of Business Development Reports and Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com
    Live Cell Imaging Market | Share & Analysis, 2020-2028
    Live cell imaging market was valued at USD 2.18 Billion in 2020 & is expected to reach USD 4.35 billion by year 2028, at a CAGR of 9.12%. live cell imaging techniques allow scientists to observe cell structures and processes in real time, and over time.
    WWW.REPORTSANDDATA.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored